First patient dosed in DMX-200 clinical trial
Filed with ASX · · 2 pages · English
Earlier from Dimerix
- Executive team bolstered through CEO & md appointment
- Quarterly Review & Appendix 4C
- Ethics Approval Received Appendix 3B and S.708A Notice
- Further US patent allowed for DMX-200
- Dual Phase 2 trials launched for CKD
Later from Dimerix
- DXB Receives Orphan Drug Designation in EU
- 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
- Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
- Appendix 4C and Quarterly Highlights
- Appendix 4C - quarterly
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix